FindTrial
Sign In

Comparison of sodium excreting effect between furosemide and indapamide combination with furosemide and metolazone combination in congestive heart failure patients

A randomized controlled trial to compare the efficacy of furosemide and indapamide combination against furosemide and metalozone combination in the sodium excreting effect in congestive heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2017/041
Enrollment
Unknown
Registered
2017-12-20
Start date
2018-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Interventions

Study setting: Rehman Medical Institute Cardiology Department,Hayatabad Peshawar Pakistan. Method of Randomization: Simple randomization into 2 groups. One group will receive combination of furosemid

Sponsors

Rehman Medical Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: New York Hear Association Grade –III New York Hear Association Grade - IV Adults from 18years to 90years of both genders will be included

Exclusion criteria

Exclusion criteria: Chronic Kidney Disease - Ultrasonographic evidence of chronic kidney disease Chronic Liver Disease - Ultrasonographic evidence of liver fibrosis Malnutrition- serum albumin concentration of less than 3g/dl

Design outcomes

Primary

MeasureTime frame
urinary sodium level in a spot urine sample [ day 1, day 3 and day 5]—

Secondary

MeasureTime frame
Measurement of 24 hour urine output and daily weight in kg [ day 1, day 3 and day 5]—

Countries

Pakistan

Contacts

Public ContactHammad Shah

Post Graduate Resident

drhammadshah@gmail.comTel: 091-5838000 ext (2181)

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026